Five specialists. One workspace.
Five agents that collaborate with you on the two jobs every biomedical researcher hates doing manually: building a bibliography for your own paper, and writing a review of the literature. Every claim each agent makes is backed by a verbatim quote from a real paper.
Literature Reviewer
Writing a state-of-the-art or systematic review paper.
A structured bibliography plus a thematic Markdown draft where every claim is backed by a verbatim quote from a real paper.
- Seed: you pick 3–5 anchor papers; we walk references and cited-by recursively to 40–60 papers (60–100 for a thesis).
- Verify: every quote we extract runs through a three-method verbatim check; nothing that fails verification reaches your draft.
- Synthesize: we cluster the verified quotes into themes, write a gap report, and draft the review with inline citations to every claim.
The review draft is written by your local LLM; citation chasing and full-text retrieval still run against the shared biomedical corpus. Best balance for most labs.
Build a thematic review on SGLT2 inhibitors in heart failure with reduced ejection fraction, irrespective of diabetes status.
Seeded with DAPA-HF, EMPEROR-Reduced, and a 2023 ESC position paper. Citation chain returned 52 candidates, 41 retained after confidence and obsolescence filtering. Three themes emerged from the verified quotes: mechanism, hard cardiovascular outcomes, and renal co-benefit. Draft Markdown delivered to your workspace, 47 quotes verified, gap report flags under-represented evidence in non-Western cohorts.
Research Bibliographer
Building the bibliography of your own research paper or thesis.
25–45 references organised by the role they play in your introduction, methods, and discussion. Every citation is backed by a verified quote.
- Decompose: we read your abstract or project aims and identify the 6–14 claims that need a citation.
- Fill: for each claim, we search PubMed, propose 3–5 candidates, and validate each one against the source paper.
- Balance: we check the funnel is complete (no missing methodological references, no over-cited subtopic), then export to BibTeX, RIS, APA, or Vancouver.
Your abstract is decomposed by your local LLM; citation enrichment and verbatim grounding still query PubMed. Best balance when your draft is sensitive but the literature is not.
Build the bibliography for a paper on dapagliflozin in HFrEF: my abstract is in the workspace.
Decomposed your abstract into 11 citation slots: 3 big-picture (HF burden), 4 known-science (SGLT2 in diabetes, then in HF), 2 gap (HFrEF irrespective of diabetes status), 2 methods (trial design). Filled with 32 verified candidates; you confirmed 28. Funnel balance check passed. Exported to BibTeX.
Cross-Validator
Stress-testing a claim across multiple papers and methods.
A one-page evidence card: direct support, partial support, indirect contradiction, direct contradiction, each with the verbatim quote and the methodology behind it.
- Locate: we hunt across PubMed and your indexed corpus for every paper that touches your claim, regardless of conclusion.
- Classify: we tag each match by stance and methodology (RCT, observational, meta-analysis, mechanistic) and weight accordingly.
- Surface: we report disagreement and replication explicitly. We never average across studies; we report the studies.
Verification runs on your local LLM; retrieval still hits PubMed. Best balance for most labs.
Validate: 'metformin reduces all-cause mortality in type 2 diabetes.'
9 studies located. 4 direct support, 3 partial support, 1 indirect contradiction (UKPDS 34 long-term follow-up nuance), 1 contextual rebuttal (post-hoc cohort). Replication grid attached. Each match carries a verbatim quote and the study design.
Literature Monitor
Staying current with PubMed without daily noise.
A morning digest of new biomedical publications matching your saved MeSH descriptors, each scored for relevance to the corpus you actually care about.
- Pick: we help you choose the right MeSH descriptors (the controlled vocabulary PubMed uses) instead of fragile keyword strings.
- Watch: the nightly PubMed delta inspects the freshly-ingested papers and emits alerts for the ones matching your tags.
- Score: each alert is ranked against the rest of your corpus, so the most relevant new papers surface first.
Relevance scoring is done by your local LLM against your private corpus; the PubMed crawl that surfaces new papers still happens on our side. Best balance when the watchlist is sensitive but PubMed isn't.
Watch for new papers on tirzepatide and HFpEF. Threshold: high relevance.
Subscription active on MeSH descriptors D000077829 (Tirzepatide) and D054144 (Heart Failure, HFpEF). Last week: 3 papers above threshold, 11 below. Expand any match to see the relevance breakdown and the verified quote that triggered the alert.
Research Assistant
Asking a biomedical question and getting a cited answer.
A concise answer with inline citations to real papers, and an honest 'no good evidence' when the literature doesn't support a claim.
- Decompose: we break your question into searchable sub-questions a paper can actually answer.
- Retrieve: we hit PubMed and your indexed corpus, fetch the full text when needed, and rank the top candidates.
- Cite: every claim in the answer is paired with the verbatim quote that supports it; unsupported claims are flagged, not invented.
The chat LLM runs on your local model; retrieval and verbatim grounding still query PubMed. Best balance when your questions are sensitive but the literature is public.
What's the current evidence for SGLT2 inhibitors in non-diabetic CKD?
DAPA-CKD (NEJM 2020) and EMPA-KIDNEY (NEJM 2023) both extend the SGLT2 benefit to non-diabetic chronic kidney disease. The relative reduction in the kidney composite endpoint was sustained across diabetic and non-diabetic strata. Two verified quotes attached, p.1438 ¶2 and p.124 ¶1.